Novo Nordisk to Unveil Cardiovascular Data at 47th ESC Congress

Bagsværd, Denmark, 27 August 2024 – Novo Nordisk has revealed plans to present 18 abstracts at the 47th Annual Congress of the European Society of Cardiology (ESC), scheduled to be held from 30 August to 2 September 2024 in London, United Kingdom. This announcement underscores Novo Nordisk's commitment to gaining deeper insights into cardiovascular disease, chronic kidney disease, and metabolic diseases such as type 2 diabetes and obesity, which frequently coexist within the same patients.

Martin Holst Lange, Executive Vice President and Head of Development at Novo Nordisk, emphasized the company's dedication to exploring clinical data across various patient populations. He highlighted the importance of understanding the influence of different risk factors on health outcomes and identifying potential treatment interventions.

The accepted data at the congress will span a range of topics, primarily focusing on the interplay between obesity, diabetes, and cardiovascular diseases. Key presentations include:

Obesity and Cardiovascular Disease:
1. An exploratory mediation analysis examining the impact of semaglutide on cardiovascular outcomes among individuals with overweight or obesity, as observed in the SELECT randomized trial.
2. Insights into cardiovascular outcomes in females with overweight and obesity, through a prespecified analysis of the SELECT trial.
3. Analysis of semaglutide's efficacy in treating atrial fibrillation and heart failure with preserved ejection fraction (HFpEF) related to obesity, using pooled data from STEP-HFpEF and STEP-HFpEF DM trials.
4. Examination of inflammation in obesity-related HFpEF, part of the STEP-HFpEF program.
5. Investigation into the effects of semaglutide on mortality and COVID-19-related deaths, based on predetermined analysis from the SELECT trial.
6. Findings from the STEP-HFpEF Program Echocardiography Substudy.

Diabetes and Cardiovascular Disease:
1. Baseline patient-reported outcomes from STRIDE, a phase 3, 52-week, randomized, double-blind, placebo-controlled trial involving patients with peripheral artery disease and type 2 diabetes.
2. Real-world data analysis assessing the cardioprotective effects of glucagon-like peptide-1 receptor agonists among individuals with type 2 diabetes in England.
3. Semaglutide's impact on cardiovascular outcomes by baseline kidney status and albuminuria in type 2 diabetes and chronic kidney disease, as revealed by the FLOW trial.
4. Pre-specified analysis of the FLOW trial to determine semaglutide's effects on heart failure outcomes among participants with type 2 diabetes and chronic kidney disease.
5. Prediction of cardiovascular risk in patients with type 2 diabetes using the SCORE2-Diabetes risk score.

Cross Trials - Cardiovascular Disease:
Several cross-trial analyses will be presented, focusing on the effects of semaglutide on clinical events in heart failure with preserved ejection fraction. These analyses integrate data from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM trials.

Systemic Inflammation:
1. Characterization of individuals with atherosclerotic cardiovascular disease, with and without chronic kidney disease, based on results from a UK electronic health record database.
2. Examination of the burden of systemic inflammation and associated health outcomes in adults with atherosclerotic cardiovascular disease managed in routine care.
3. Study on systemic inflammation and its link to mortality risk in patients with atherosclerotic cardiovascular disease and chronic kidney disease.
4. Analysis of healthcare resource utilization and costs related to systemic inflammation in individuals with atherosclerotic cardiovascular disease and chronic kidney disease.
5. Population-based study in Spain exploring systemic inflammation in patients with atherosclerotic cardiovascular and chronic kidney disease using electronic medical records from a primary care database.
6. Survey assessing awareness and perceptions of cardiologists towards systemic inflammation in atherosclerotic cardiovascular disease, conducted across five geographical regions.

Novo Nordisk, founded in 1923 and headquartered in Denmark, employs around 69,000 people across 80 countries. The company remains dedicated to pioneering scientific breakthroughs, expanding access to medications, and working towards the prevention and cure of serious chronic diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!